Inventiva share rebounds 2.5% but remains in extreme oversold RSI at 18
The Dijon biotech company specializing in fibrotic and metabolic diseases remains in a significantly deteriorated technical configuration, with a price trading well below its long-term moving averages.
An intraday rebound within a quarterly and annual chart deeply in the red
The Inventiva share rose 2.53% to €2.84 in morning trading, ranking among the strongest gainers in the SBF 120. This movement comes after a difficult week: the stock fell 14.48% over the past seven days and declined 28.32% over the month. Over one year, the loss reaches 39.36%, placing the price well below medium-term equilibrium levels.
The technical configuration remains dominated by accumulated downward pressure. The price trades at €2.84, down 21.47% below the 20-day MA at €3.61 and 25.79% below the 50-day MA at €3.82, while the 200-day MA at €4.31 sits 34.22% above, levels that today's rebound does not yet threaten. The RSI at 18 signals an extreme oversold configuration, consistent with the amplitude of the monthly and weekly decline, although no sustained reversal is discernible at this stage based solely on market data.
H1 2026 results expected Monday, amid reduced financial visibility
Inventiva will publish its financial results for the first half of 2026 on Monday, September 28. The context for this publication remains tense: upon the release of H1 2026 on July 30, the company reported cash of €166 million, but with no revenue recorded over the period, compared with €4.5 million a year earlier. The cash horizon as it stood at that date was limited to the end of the second quarter of 2027 without additional financing, with cash that the company itself presented as insufficient to cover operational needs for the coming twelve months.
Financing operations had been announced in June 2026, including an equity offering of €103 million and a financing operation of €75 million, supplemented by additional conditional tranches. Furthermore, Chris Benecchi was appointed Chief Operating Officer in early September, ahead of the results from the Phase 3 NATiV3 pivot study expected in the fourth quarter of 2026. The September 28 publication will provide an updated assessment of the cash situation and progress of the clinical program.
